Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 4Colorectal Neoplasms 3Neoplasm Metastasis 2Carcinoma, Renal Cell 2Solid Tumors 1Rectal Neoplasms 1Neoplasms 1Kidney Neoplasms 1Colonic Neoplasms 1Brain Neoplasms 1Advanced Solid Tumor 1

Interventions

cabozantinib 5Nivolumab 4Ipilimumab 4Axitinib 4pembrolizumab 3Blood Specimen Collection 3zimberelimab 2atezolizumab 2Surveys and Questionnaires 2Sunitinib 2Irinotecan 2temsirolimus 1spartalizumab 1salicylhydroxamic acid 1palbociclib 1orellanine 1olaparib 1liposomal doxorubicin 1lenvatinib 1gallium Ga 68 dotatate 1fludarabine 1brodalumab 1belzutifan 1aldesleukin 1adagrasib 1Vincristine 1Temozolomide 1Taxes 1Selenomethionine 1Ropivacaine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × adagrasib × 90 days × Clear all
NCT06026410 2026-04-14

FIT-001

Kura Oncology, Inc.

Phase 1 Recruiting
300 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡